[A21-58] Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Last updated 02.08.2021
Project no.:
A21-58
Commission:
Commission awarded on 03.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Pretreated and treatment-naive patients with at least 4 migraine days per month who are candidates for conventional migraine prophylaxis (subpopulation of the approved therapeutic indication)
Indication of a non-quantifiable added benefit (at least “considerable”).
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A18-71 | Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V | Commission completed |